AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03550209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCPUFA Oil Supplement
Description: 25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
Study NCT03550209 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Canola Oil Placebo
Description: Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
Study NCT05504954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA-SA (intervention group)
Description: The IMARA-SA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA-SA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA-SA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
Study NCT02555878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
Study NCT02555878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally once daily for 180 days.
Study NCT03024372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Fistula creation with sutures
Description: End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
Study NCT03024372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Fistula creation with clips
Description: End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
Study NCT05504954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion control group
Description: The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
Study NCT02390011 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Study NCT02289222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
Study NCT00594139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous neobladder construct
Description: provision of an autologous neo-bladder construct
Study NCT01009567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
Study NCT01009567 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Receive human albumin 20% infusion
Study NCT02289222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
Study NCT02289222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is given at 40 mg orally weekly
Study NCT03724565 — intervention group
Intervention type: PROCEDURE
Intervention: Method of endoscopic procedure
Description: Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
Study NCT05267457 — intervention group
Intervention type: OTHER
Intervention: Plasma vanadium concentration
Description: Plasma vanadium concentrations were measured using inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 7700 Series, United States)
Study NCT01725555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasted treatment: AXL1717
Study NCT01725555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fed treatment: AXL1717
Study NCT03785990 — intervention group
Intervention type: OTHER
Intervention: adipose tissue
Description: taking a sample of the adipose tissue during operation
Study NCT00594243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction program
Description: 8-week mindfulness based stress reduction program
Study NCT00594243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list control
Description: No treatment given.
Study NCT02852616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Exposure Therapy
Description: 8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
Study NCT03785990 — intervention group
Intervention type: OTHER
Intervention: blood
Description: taking a blood sample when a peripheral venous catheter is inserted before operation
Study NCT03785990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PEAPOD
Description: Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)
Study NCT00756145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: At start of the session, at the inlet line
Description: Injection of LMWH at the inlet line, at the start of the hemodiafiltration session
Study NCT00756145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5 minutes after the start of the session, at the inlet line
Description: Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session
Study NCT00756145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: At the start of the session, at the outlet line
Description: Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
Study NCT01135498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Intravenous repeating dose
Study NCT01135498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eloxatin
Description: Intravenous repeating dose
Study NCT01135498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: Oral repeating dose
Study NCT00589264 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc
Description: 10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
Study NCT00589264 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron + copper
Description: 10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
Study NCT02399020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training
Description: manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
Study NCT03160170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SISTER device
Description: Use of the Suction-Integrated Surgical Tissue Elevator \& Retractor (SISTER) device during surgery
Study NCT02247544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
Study NCT01170650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC145
Description: IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
Study NCT01170650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)
Description: 50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
Study NCT01170650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)
Description: 50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
Study NCT01170650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
Study NCT01170650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC20
Description: During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
Study NCT01170650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC20
Description: During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
Study NCT00008177 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV
Study NCT00008177 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation
Study NCT00008177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT00008177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT00008177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00008177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given orally or IV
Study NCT00008177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given orally or IV
Study NCT00008177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04142827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Humidification
Description: myAirvo2 gives at home for long therapy treatment
Study NCT02583269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01135498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: Oral repeating dose
Study NCT01849874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162, MEK inhibitor; oral
Description: multiple dose, single schedule
Study NCT02583269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscadine Grape Skin Extract
Description: Given PO
Study NCT01849874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice chemotherapy
Description: Patients will receive one of the following chemotherapies as determined by the physician:~* Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~* Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~* Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)
Study NCT02583269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03165097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-709478
Description: Hard gelatine capsules for oral administration
Study NCT03165097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching ACT-709478 capsules
Study NCT03165097 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Midazolam oral solution (2 mg/mL) applied with a syringe
Study NCT03990974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative antimicrobial prophylaxis
Description: The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
Study NCT03990974 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No postoperative antimicrobial prophylaxis
Description: Patients will receive no antibiotics after hepatectomy unless necessary.
Study NCT03875417 — intervention group
Intervention type: PROCEDURE
Intervention: liver resection
Description: resection of one or more HCC nodules within the liver
Study NCT03875417 — intervention group
Intervention type: PROCEDURE
Intervention: Thermic ablation
Description: ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves
Study NCT03875417 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter arterial chemoembolization
Description: embolization of HCC nodule via drug-eluted microbeads.
Study NCT00005850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
Study NCT00005850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: 10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
Study NCT00005850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
Study NCT01288430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2248
Description: Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Know Your Baby Language Curriculum
Description: Early language activities that parents can do with their infants
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading Aloud Language Curriculum
Description: Early language activity that parents can do with their infants
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sing A Long Language Curriculum
Description: Early language activity that parents can do with their infants
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mimicking First Sounds Language Curriculum
Description: Early language activity that parents can do with their infants
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language Games and Narrating Your Day Language Curriculum
Description: Early language activity that parents can do with their infants
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding Safety
Description: Part of Health and Safety Curriculum
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Car Seat Safety
Description: Part of Health and Safety Curriculum
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bath Safety
Description: Part of Health and Safety Curriculum
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Back to Sleep/SIDS prevention
Description: Part of Health and Safety Curriculum
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Taking a Temperature and Signs of Infection
Description: Part of Health and Safety Curriculum
Study NCT02528227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infection Control Measures and Vaccine Information
Description: Part of Health and Safety Curriculum
Study NCT03165097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-709478 combined with midazolam
Description: Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
Study NCT03708146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: 25 mg and 100 mg tablets; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), BIA 5-1058 will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), BIA 5-1058 will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water.
Study NCT02375802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose-derived stromal cells
Description: Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
Study NCT02375802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-derived stromal cells
Study NCT03708146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), placebo will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), placebo will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water.
Study NCT03844737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisuXL®
Description: Treatment of discomfort forms of the ocular surface, in professional water-polo athletes exposed to pool water for prolonged periods.
Study NCT02429440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peptide vaccine
Description: subcutaneous
Study NCT02429440 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peptide vaccine
Description: subcutaneous
Study NCT02429440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage Colony Stimulating Factor
Description: intradermal
Study NCT02429440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montanide ISA-51
Description: subcutaneous
Study NCT04377568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP)
Description: Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL
Study NCT00847314 — intervention group
Intervention type: DRUG
Intervention: Testosterone Undeconate (Nebido-R, BAY86-5037)
Description: Male patients > 35yrs in medical practices fulfilling all criteria for documentation.
Study NCT01030900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath
Description: campath plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and rituximab every 3 weeks for up to 6 cycles
Study NCT01030900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and campath every 3 weeks for up to 6 cycles
Study NCT01030900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles
Study NCT04628624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 8 week supplementation period, with participants consuming 2 capsules per day containing potato starch
Study NCT04628624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GTE 1
Description: 8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)
Study NCT04628624 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GTE 2
Description: 8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
Study NCT02485769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Suspension
Study NCT02485769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension